Evidence map›Paper›PMID 31276119›Full record

ArticleEC psychology and psychiatry2019

Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

Kenneth Blum, David Baron, Rajendra D Badgaiyan, Mark S Gold

Open access · greenAbstract readComment
PubMed Full text at PMC
In one paragraph

Article in EC psychology and psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Kenneth Blum *Western University Health Sciences, Graduate School of Biomedical Sciences, Pomona, CA, USA.
David Baron *Western University Health Sciences, Graduate School of Biomedical Sciences, Pomona, CA, USA.
Rajendra D Badgaiyan *Department of Psychiatry, Ichan School of Medicine at Mount Sinai, New York, NY.
Mark S Gold *Division of Nutrigenomics, Geneus Health, LLC., San Antonio, TX., USA.
Western University of Health Sciences · USWright State University · US

Funding

Dopamine Neurotransmission in Tourette SyndromeR01NS073884 · NINDS · UNIVERSITY OF MINNESOTA · PI BADGAIYAN, RAJENDRA D · 2012 to 2016
$2.2M
A Systematic Medical Approach to Reward Transformation (SMART) for Brain Health in Opioid Use DisorderR41MD012318 · NIMHD · VERSA INTEGRATED SOLUTIONS, INC. · PI BLUM, KENNETH, GONDRE-LEWIS, MARJORIE C · 2017 to 2017
$221k
Dopamine Neurotransmission in AddictionI01CX000479 · VA · VA WESTERN NEW YORK HEALTHCARE SYSTEM · PI BADGAIYAN, RAJENDRA D · 2013 to 2014
–
CSRD VA I01 CX000479NIMHD NIH HHS R41 MD012318NINDS NIH HHS R01 NS073884
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID31276119
PMCPMC6604646
OpenAlexW2984140753

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.